Ann: IHL commences manufacturing of skin therapeutics, page-44

FreeBobby2002 - TV summed it up for me but I will highlight IHL-42X commencing Phase 2 / 3 Trials in the USA Q1.

Lets look as RESMED as a reference. ((rough numbers))
RESMED's MC is currently around 52Billion.
RESMED did around $950M of revenue last quarter with Profit of around $250M.
RESMED are predicting to improve 250M lives in 2025. ((I think we will get a good portion of these))
I am not saying we are RESMED but if our product makes it through phase 2/3 - we will be a major competitor with an easier to use and tolerate product.

At $1.00 we are worth around 1.5B - This would mean RESMED would still be worth 34x more than us. ((rough numbers))

Option expiry date is 5 months away. I'm not pumping - I am a true believer in the pharmaceutical combinations this business have and in managements ability to deliver. 5 Months is a long time with this management team and the amount of current and future clinical programs underway.

Rough number research while I play basket ball with my boy's so please correct if someone wants to dig deeper.